Catalog No.
DHC35301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-nd
Clonality
Monoclonal
Target
Vimentin, VIM
Concentration
4.12 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08670
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CLN G11, CAS: 499212-74-7
Clone ID
Pritumumab
Pritumumab, the first therapeutic antibody for glioma patients, PMID: 29036806
A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin, PMID: 30539482
Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab, PMID: 19996527
Unconventional immunotherapy with an unconventional target, PMID: 32925025
The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy, PMID: 23856243
Characterization of pritumumab in murine models and primate safety study., PMID:40128557
Cell surface vimentin: a natural human immune response target for immunotherapy., PMID:40051499
A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases., PMID:39465217
Unconventional immunotherapy with an unconventional target., PMID:32925025
A Binding Potency Assay for Pritumumab and Ecto-Domain Vimentin., PMID:30539482
Pritumumab, the first therapeutic antibody for glioma patients., PMID:29036806
The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy., PMID:23856243
Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab., PMID:19996527
For research use only. Not for human or drug use.
